Clovate therapy of steroid-sensitive dermatoses

Elena S. Snarskaya , L. M Shnakhova

Russian Journal of Skin and Venereal Diseases ›› 2014, Vol. 17 ›› Issue (6) : 18 -21.

PDF
Russian Journal of Skin and Venereal Diseases ›› 2014, Vol. 17 ›› Issue (6) : 18 -21. DOI: 10.17816/dv36906
Articles
research-article

Clovate therapy of steroid-sensitive dermatoses

Author information +
History +
PDF

Abstract

The choice of a topical corticosteroid drug is a difficult problem for practical physician. Modern topical glucocorticosteroids are the most effective, as they unite the positive characteristics of previous drugs, their activity is comparable to that of fluorinated glucocorticoids, and their untoward effects (characteristic of hydrocortisone acetate) are the minimum. It is a class of modern potent drugs. One of them is Clovate® (active substance 0.05% clobethasol propionate; "Valeant", Canada). Prescription of a short course of Clovate during exacerbation and progress of severe psoriasis forms is safe and not associated with subclinical signs of augmenting adrenosuppression. "Step-down" therapy leads to a rapid clinical effect without side effects. Experience gained in the use of this method is presented.

Keywords

steroid-sensitive dermatoses / psoriasis vulgaris / topical therapy / IV generation glucocorticoids / clobethasol propionate / Clovate / "step-down" therapy

Cite this article

Download citation ▾
Elena S. Snarskaya, L. M Shnakhova. Clovate therapy of steroid-sensitive dermatoses. Russian Journal of Skin and Venereal Diseases, 2014, 17(6): 18-21 DOI:10.17816/dv36906

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Sterry W., Asadullah K. Topical glucocorticoid therapy in dermatology. Ernst. Schering Res. Found Workshop. 2002; 40: 39-54.

[2]

Pearce D.J., Stealey K.H., Balkrishnan R., Fleischer A.B. Jr., Feldman S.R. Psoriasis treatment in the United Stated at the end of the 20th century. Int. J. Dermatol. 2006; 45(4): 370-4.

[3]

Белоусова Т.А. Рациональное применение наружных глюкокортикостероидов в общей клинической практике. Русский медицинский журнал. 2006; 29: 2090-4.

[4]

Короткий Н.Г., Гамаюнов Б.Н., Тихомиров А.А. Практика применения новых наружных средств в лечении атопического дерматита. Клиническая дерматология и венерология. 2010; 1: 61-6.

[5]

Бакулев А.Л., Кравченя С.С. Об эффективности и безопасности применения клобетазола пропионата коротким курсом у больных псориазом в фазе прогрессирования. Вестник дерматологии и венерологии. 2012; 3: 121-5.

[6]

Пинегин Б.В., Иванов О.Л., Пинегин В.Б. Роль клеток иммунной системы и цитокинов в развитии псориаза. Роcсийский журнал кожных и венерических болезней. 2013; 3: 19-24.

[7]

Хлебникова А.Н. Современные подходы к наружной терапии псориаза. Вестник дерматологии и венерологии. 2012; 1: 87-8.

[8]

Castela E.L., Archier J.V., Devaux S., Gallini A., Aractingi S., Cribier B., et al. Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal suppression and skin atrophy. J. Eur. Acad. Dermatol. Venerol. 2012; 26(Suppl. 3): 47-51. doi: 10.1111/j.1468-3083.2012.04523.x.

[9]

Weston W.L., Fennessey P.V., Morelli J.V., Schwab H., Mooney J., Samson C., et al. Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent topical steroids by standard endocrine function testing and gas chromatographic mass spectrometry. J. Invest. Dermatol. 1988; 90(4): 532-5.

RIGHTS & PERMISSIONS

Eco-Vector

AI Summary AI Mindmap
PDF

138

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/